Clinical Trials
39 trialsConnect® MM- The Multiple Myeloma Disease Registry
Celgene
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
University of Chicago
AMBROBiMM
Assistance Publique - Hôpitaux de Paris
FRE
Hackensack Meridian Health
Corneal Findings in Patients Treated With Belantamab Mafodotin
Medical University of Vienna
Blood Samples to Identify Biomarkers of Busulfan
Fred Hutchinson Cancer Center
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Takeda
Multiple Myeloma Patient Registry
Janssen Scientific Affairs, LLC
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Strata Oncology
PaCE-MM
UNC Lineberger Comprehensive Cancer Center
The clonoSEQ® Watch Registry
Adaptive Biotechnologies
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Travera Inc
The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
St. Petersburg State Pavlov Medical University
MMRF CureCloud Research Initiative
Multiple Myeloma Research Foundation
Quality of Life in Patients With Multiple Myeloma-validation Study
Zurich University of Applied Sciences
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Cogent Biosciences, Inc.
EPA-MMBR
Celgene
MYMO
Centre Hospitalier Universitaire de Nīmes
GENOMGUS
Rennes University Hospital
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
National Institutes of Health Clinical Center (CC)
Lenalidomide Adherence in Older Adults
Washington University School of Medicine
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
Juno Therapeutics, a Subsidiary of Celgene
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
N1
CureOne
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Vanderbilt-Ingram Cancer Center
Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research
Dartmouth-Hitchcock Medical Center
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
University of Arkansas
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
OHSU Knight Cancer Institute
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Celgene
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
Case Comprehensive Cancer Center
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
Vanderbilt University
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Columbia University
SCRI Tissue Testing Registry
SCRI Development Innovations, LLC
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies
University of California, San Francisco
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Studying Fentanyl in Patients With Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
Vanderbilt-Ingram Cancer Center
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
City of Hope Medical Center